Celltrion Healthcare Secures 'Remsima' Contract in Brazil for Second Consecutive Year

342,000 Vials Exclusively Supplied by Brazilian Government
"Will Strengthen Position in Latin American Market"

[Asia Economy Reporter Myunghwan Lee] Celltrion Healthcare announced on the 10th that it has succeeded in winning the bid for the second consecutive year for the autoimmune disease treatment biosimilar 'Remsima' (generic name infliximab) in Brazil. With this order, Celltrion Healthcare will exclusively supply a total of 342,000 vials of Remsima to the Brazilian federal government market in the first half of this year.

The Brazilian federal government market, where Celltrion Healthcare won the bid, accounts for 60% of the entire infliximab market, making it the largest market. Considering the quantities supplied to state governments and others along with this federal government bid, Celltrion Healthcare explained that Remsima is expected to record a market share exceeding 80% in the Brazilian infliximab market.

Celltrion Healthcare has focused on securing Brazil, a key market, to strengthen its presence in the Latin American region. Through an aggressive bidding strategy, it has won bids not only for Remsima but also for all products including Truxima (generic name rituximab) and Herzuma (generic name trastuzumab). The launch of Remsima SC (subcutaneous injection form), approved last November, is scheduled for the first half of this year, and marketing is expected to be strengthened through portfolio expansion.

Celltrion Healthcare emphasized that achievements in Latin American regions other than Brazil are also becoming visible. In major countries such as Colombia, Chile, and Peru, Remsima already holds more than 80% market share, and in Costa Rica, Ecuador, and others, Celltrion Healthcare’s oncology antibody biosimilar drugs are recording market shares exceeding 95%, according to the company.

Kang Kyungdoo, head of Celltrion Healthcare’s Latin America region, stated, "Following 2022, Remsima is again exclusively supplied to the Brazilian federal government market this year, confirming once more that our products have gained high preference and trust among local medical staff and patients," and added, "We will concentrate all our capabilities on strengthening our presence in the Latin American region."